Pr Alexander M. Eggermont of Institut Gustav Roussy in Paris and study coordinator of EORTC trial 18071, presented the initial efficacy and safety results from that phase III trial at ASCO 2014 in Chicago. This trial showed that adjuvant therapy with ipilimumab (Yervoy) for patients with high-risk stage III melanoma significantly improved recurrence-free survival. An overview of the trial results were reported 06 June 2014 in The ASCO Post.
Merck’s KEYTRUDA® (pembrolizumab) Significantly Improved Recurrence-Free Survival Compared to Placebo as Adjuvant Therapy in Patients with Stage 3 Resected High-Risk Melanoma (EORTC1325/KEYNOTE-054)
8 Jan 2018
1 Mar 2018